Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases
Go back to Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases| (NASDAQ: CRDL) | Delayed: 1.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.01 | 52 Week High | $ | |||
| Open | $1.00 | 52 Week Low | $ | |||
| Day High | $1.02 | P/E | N/A | |||
| Day Low | $0.98 | EPS | $ | |||
| Volume | 253,734 | |||||

